Active substance
Dexketoprofen
- SFDA 3
- NHS prices 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| KETESSE | 25 mg/ml | Concentrate and solvent for solution for infusion · Intramuscular and intravenous use | 20 Ampoule | SAR 97.95 | NCE · Prescription | Menarini International O. L. S.A | Valid |
| KETESSE | 25 mg/ml | Concentrate and solvent for solution for infusion · Intramuscular and intravenous use | 5 Ampoule | SAR 24.50 | NCE · Prescription | Menarini International O. L. S.A | Valid |
| KETESSE 25MG F.C.TABLET | 25 mg | Film-coated tablet · Oral use | 20 Blister | SAR 16.90 | NCE · Prescription | A MENARINI INDUSTRIE FARMACEUTICHE S.R.L | Valid |
Indications — CHI Daman Drug Formulary
NON-INFECTIOUS UVEITIS; RENAL AND URETERIC STONES; SICKLE CELL DISEASE - PAIN MANAGEMENT
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Dexketoprofen 25mg tablets | £3.67 | 20 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Dexketoprofen 25mg tablets | £9.18 | 50 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.